The Food and Drug Administration has revealed that the maker of a brand of eye drops linked to an outbreak of fatal bacterial infections failed to follow multiple safety protocols.
The FDA visited a Global Pharma Healthcare facility in India for an inspection in mid-February and found dozens of issues ranging from dirty equipment and clothing to missing safeguards and procedures.
The inspection came two-and-a-half weeks after the company voluntarily recalled the EzriCare artificial tears product because of possible contamination.
When the recall was issued, there were already 55 reports of adverse events, including eye infections, permanent loss of vision, and at least one death from a bloodstream infection.
Fresh off of speaking at the UN, Amalya Yeghoyan, Executive Director of FAR’s Gyumri Information Technology Center, discusses her work to empower women through tech.
Veetahl Eilat-Raichel, Founder and CEO of Sorbet, shares how employees can harness the value of their time off – and how companies can use PTO to employees’ benefit.
Brooke May, Managing Partner at Evans May Wealth, weighs in on how the market is expected to perform through the rest of 2024, plus why she’s still bullish on tech but cautious when it comes to financials.
Pete Nicoletti, Global CISO at Check Point, explains why it’s so difficult to legislate against A.I. disinformation and why it’s a concern going into the 2024 election.
Michelle Freyre, Clinique Global Brand President, discusses the company's latest ventures and why skin advice should always come from a trusted source.
